---
title: "New phase I methods in escalation"
subtitle: "Introducing new methods in `escalation` for TPI, mTPI and Neuenschwander et al.'s design for phase I trials, plus MCMC CRM methods."
summary: "Introducing new methods in `escalation` for TPI, mTPI and Neuenschwander et al.'s design for phase I trials, plus MCMC-based CRM methods."
authors: 
  - admin
categories:
- Code
tags:
  - escalation
  - R
  - DoseFinding
projects: []
date: '2020-10-20'
lastmod: '2020-10-20T17:07:58Z'
draft: false
featured: no
image:
  caption: 'Photo by [Samuel Isaac on Unsplash](https://unsplash.com/photos/83AdeG3iPMk)'
  focal_point: ''
  preview_only: no
bibliography: library.bib
---

<script src="index_files/htmlwidgets/htmlwidgets.js"></script>
<script src="index_files/viz/viz.js"></script>
<link href="index_files/DiagrammeR-styles/styles.css" rel="stylesheet" />
<script src="index_files/grViz-binding/grViz.js"></script>


<div id="introduction" class="section level2">
<h2>Introduction</h2>
<p>This week I updated the <a href="https://CRAN.R-project.org/package=escalation"><code>escalation</code></a> <span class="citation">(Brock 2020)</span> package on CRAN with new methods to implement several phase I and phase I/II dose-finding designs.
This post describes the addition of the phase I methods TPI, mTPI, and the logistic model method of <span class="citation">Neuenschwander, Branson, and Gsponer (2008)</span>, and also the addition of MCMC-based CRM methods.</p>
</div>
<div id="tpi" class="section level2">
<h2>TPI</h2>
<p>The toxicity probability interval (TPI) design was introduced by <span class="citation">Ji, Li, and Bekele (2007)</span>.
It is one of a series of dose-finding trial designs that works by partitioning the probability of toxicity into a set of intervals.
These designs make dose-selection decisions that are determined by the interval in which the probability of toxicity for the current dose is believed to reside.</p>
<p>Core to this design is a beta-binomial Bayesian conjugate model.
For hyperparameters <span class="math inline">\(\alpha\)</span> and <span class="math inline">\(\beta\)</span>, let the probability of toxicity at dose <span class="math inline">\(i\)</span> be <span class="math inline">\(p_i\)</span>, with prior distribution</p>
<p><span class="math display">\[p_i \sim Beta(\alpha, \beta).\]</span></p>
<p>If <span class="math inline">\(n_i\)</span> patients have been treated at dose <span class="math inline">\(i\)</span>, yielding <span class="math inline">\(x_i\)</span> toxicity events, the posterior distribution is</p>
<p><span class="math display">\[ p_i | data \sim Beta(\alpha + x_{i}, \beta + n_{i} - x_{i}).\]</span></p>
<p>Using this distribution, let the standard deviation of <span class="math inline">\(p_i\)</span> be denoted by <span class="math inline">\(\sigma_i\)</span>.
The design seeks a dose with probability of toxicity close to some pre-specified target level, <span class="math inline">\(p_T\)</span>.
The entire range of possible values for <span class="math inline">\(p_i\)</span> can be broken up into the following intervals:</p>
<ul>
<li>The underdosing interval (UI), defined as <span class="math inline">\((0, p_{T} - K_{2} \sigma_{i})\)</span>;</li>
<li>The equivalence interval (EI), defined as <span class="math inline">\((p_{T} - K_{2} \sigma_{i}, p_{T} + K_{1} \sigma_{i})\)</span>;</li>
<li>The overdosing interval (OI), defined as <span class="math inline">\((p_{T} + K_{1} \sigma_{i}, 1)\)</span>;</li>
</ul>
<p>for pre-specified model constants, <span class="math inline">\(K_1, K_2\)</span>.
These intervals are mutally-exclusive and mutually-exhaustive, meaning that every possible probability belongs to precisely one of them.
In other words, these intervals form a partition of the probability space, <span class="math inline">\((0, 1)\)</span>.</p>
<p>Using the posterior distribution, we can calculate the three probabilities</p>
<p><span class="math display">\[p_{UI} = Pr(p_i \in \text{UI}), \enspace p_{EI} = Pr(p_i \in \text{EI}), \enspace p_{OI} = Pr(p_i \in \text{OI}).\]</span></p>
<p>By definition, <span class="math inline">\(p_{UI} + p_{EI} + p_{OI} = 1\)</span>.
The logical action in the dose-finding trial depends on which of these three probabilities is the greatest.
If <span class="math inline">\(p_{UI} &gt; p_{EI}, p_{OI}\)</span>, then the current dose is likely an underdose, so our desire should be to escalate dose to <span class="math inline">\(i+1\)</span>.
In contrast, if <span class="math inline">\(p_{OI} &gt; p_{UI}, p_{EI}\)</span>, then the current dose is likely an overdose and we will want to de-escalate dose to <span class="math inline">\(i-1\)</span> for the next patient.
If <span class="math inline">\(p_{EI} &gt; p_{UI}, p_{OI}\)</span>, then the current dose is deemed sufficiently close to <span class="math inline">\(p_T\)</span> and we will want to stay at dose-level <span class="math inline">\(i\)</span>.</p>
<p>Further to these rules regarding dose-selection, the following rule is used to avoid recommending dangerous doses.
A dose is deemed inadmissible for being excessively toxic if</p>
<p><span class="math display">\[ Pr(p_{i} &gt; p_{T} | data) &gt; \xi,\]</span></p>
<p>for a certainty threshold, <span class="math inline">\(\xi\)</span>.
If a dose is excluded by this rule, it should not be recommended by the model.
Irrespective the probabilities <span class="math inline">\(p_{UI}, p_{EI}, p_{OI}\)</span>, the design will recommend to stay at dose <span class="math inline">\(i\)</span> rather than escalate to a dose previously identified as being inadmissible.
Furthermore, the design will advocate stopping if the lowest dose is inferred to be inadmissible.</p>
<p>In their paper, the authors demonstrate acceptable operating performance using <span class="math inline">\(\alpha = \beta = 0.005\)</span>, <span class="math inline">\(K_{1} = 1\)</span>, <span class="math inline">\(K_{2} = 1.5\)</span> and <span class="math inline">\(\xi = 0.95\)</span>.
See <span class="citation">Ji, Li, and Bekele (2007)</span> for full details.</p>
<div id="implementation-in-escalation" class="section level3">
<h3>Implementation in <code>escalation</code></h3>
<p>Let us specify the model that the authors investigate in their publication:</p>
<pre class="r"><code>library(escalation)

model &lt;- get_tpi(num_doses = 5, target = 0.3, alpha = 0.005, beta = 0.005, 
                 k1 = 1, k2 = 1.5, exclusion_certainty = 0.95)</code></pre>
<p>As with all models in <code>escalation</code>, we fit the model to some outcomes using code like:</p>
<pre class="r"><code>fit &lt;- model %&gt;% fit(&#39;1NNT&#39;) </code></pre>
<p>and learn the dose recommended for the next patient(s):</p>
<pre class="r"><code>fit %&gt;% recommended_dose()</code></pre>
<pre><code>## [1] 1</code></pre>
<p>In their Table 1, <span class="citation">Ji, Li, and Bekele (2007)</span> recommend some model choices based on notional cohort outcomes.
We can reproduce their findings using, for example:</p>
<pre class="r"><code>model %&gt;% 
  get_dose_paths(cohort_sizes = 6, next_dose = 2) %&gt;% 
  graph_paths()</code></pre>
<div id="htmlwidget-1" style="width:672px;height:480px;" class="grViz html-widget"></div>
<script type="application/json" data-for="htmlwidget-1">{"x":{"diagram":"digraph {\n\ngraph [layout = \"neato\",\n       outputorder = \"edgesfirst\",\n       bgcolor = \"white\"]\n\nnode [fontname = \"Helvetica\",\n      fontsize = \"10\",\n      shape = \"circle\",\n      fixedsize = \"true\",\n      width = \"0.5\",\n      style = \"filled\",\n      fillcolor = \"aliceblue\",\n      color = \"gray70\",\n      fontcolor = \"gray50\"]\n\nedge [fontname = \"Helvetica\",\n     fontsize = \"8\",\n     len = \"1.5\",\n     color = \"gray80\",\n     arrowsize = \"0.5\"]\n\n  \"1\" [label = \"2\", fontcolor = \"#FDE725FF\", fillcolor = \"#2A788EFF\"] \n  \"2\" [label = \"3\", fontcolor = \"#440154FF\", fillcolor = \"#22A884FF\"] \n  \"3\" [label = \"2\", fontcolor = \"#FDE725FF\", fillcolor = \"#2A788EFF\"] \n  \"4\" [label = \"2\", fontcolor = \"#FDE725FF\", fillcolor = \"#2A788EFF\"] \n  \"5\" [label = \"1\", fontcolor = \"#7AD151FF\", fillcolor = \"#414487FF\"] \n  \"6\" [label = \"1\", fontcolor = \"#7AD151FF\", fillcolor = \"#414487FF\"] \n  \"7\" [label = \"1\", fontcolor = \"#7AD151FF\", fillcolor = \"#414487FF\"] \n  \"8\" [label = \"1\", fontcolor = \"#7AD151FF\", fillcolor = \"#414487FF\"] \n\"1\"->\"2\" [label = \"NNNNNN\"] \n\"1\"->\"3\" [label = \"NNNNNT\"] \n\"1\"->\"4\" [label = \"NNNNTT\"] \n\"1\"->\"5\" [label = \"NNNTTT\"] \n\"1\"->\"6\" [label = \"NNTTTT\"] \n\"1\"->\"7\" [label = \"NTTTTT\"] \n\"1\"->\"8\" [label = \"TTTTTT\"] \n}","config":{"engine":"dot","options":null}},"evals":[],"jsHooks":[]}</script>
<p>I.e. if there are six patients at the current dose, this particular parameterisation will only advocate escalation if exactly zero toxicities are seen.
If one or two toxicities are seen, the design advocates staying at dose 2, otherwise deescalation is recommended.</p>
</div>
</div>
<div id="mtpi" class="section level2">
<h2>mTPI</h2>
<p>The modified toxicity probability interval (mTPI) design was introduced by <span class="citation">Ji et al. (2010)</span>.
As the name suggests, it is a modification of the earlier TPI design.
mTPI is very similar to TPI, again using a method that partitions the probability of toxicity into a set of intervals.</p>
<p>This design uses a beta-binomial Bayesian conjugate model.
For hyperparameters <span class="math inline">\(\alpha\)</span> and <span class="math inline">\(\beta\)</span>, let the probability of toxicity at dose <span class="math inline">\(i\)</span> be <span class="math inline">\(p_i\)</span>, with prior distribution</p>
<p><span class="math display">\[p_i \sim Beta(\alpha, \beta).\]</span></p>
<p>If <span class="math inline">\(n_i\)</span> patients have been treated at dose <span class="math inline">\(i\)</span>, yielding <span class="math inline">\(x_i\)</span> toxicity events, the posterior distribution is</p>
<p><span class="math display">\[ p_i | data \sim Beta(\alpha + x_{i}, \beta + n_{i} - x_{i}).\]</span></p>
<p>The design seeks a dose with probability of toxicity close to some pre-specified target level, <span class="math inline">\(p_T\)</span>.
The entire range of possible values for <span class="math inline">\(p_i\)</span> can be broken up into the following intervals:</p>
<ul>
<li>The underdosing interval (UI), defined as <span class="math inline">\((0, p_{T} - \epsilon_{1})\)</span>;</li>
<li>The equivalence interval (EI), defined as <span class="math inline">\((p_{T} - \epsilon_{1}, p_{T} + \epsilon_{2})\)</span>;</li>
<li>The overdosing interval (OI), defined as <span class="math inline">\((p_{T} + \epsilon_{2}, 1)\)</span>;</li>
</ul>
<p>for pre-specified model constants, <span class="math inline">\(\epsilon_{1}, \epsilon_{2}\)</span>.
These intervals are mutally-exclusive and mutually-exhaustive, meaning that every possible probability belongs to precisely one of them.
In other words, these intervals form a partition of the probability space, <span class="math inline">\((0, 1)\)</span>.</p>
<p>For a continuous random variable <span class="math inline">\(X\)</span> with cumulative probability mass function <span class="math inline">\(F(x)\)</span> (i.e. <span class="math inline">\(Pr(X &lt; x) = F(x)\)</span>), the authors define the unit probability mass (UPM) for an interval <span class="math inline">\((a, b)\)</span> to be <span class="math inline">\((F(b) - F(a)) / (b - a)\)</span>.
That is, the UPM is the probability mass in an interval divided by the width of the interval, and can be interpreted as the average probability density of the interval.</p>
<p>Then, using the posterior distribution identified above, we calculate the three UPMs</p>
<p><span class="math display">\[UPM_{UI} = Pr(p_i \in \text{UI}) / (p_{T} - \epsilon_{1}),\]</span>
<span class="math display">\[UPM_{EI} = Pr(p_i \in \text{EI}) / (\epsilon_{1} + \epsilon_{2}),\]</span></p>
<p>and</p>
<p><span class="math display">\[UPM_{OI} = Pr(p_i \in \text{OI}) / (1 - p_{T} + \epsilon_{2}).\]</span></p>
<p>The logical action in the dose-finding trial depends on which of these three quantities is the greatest.
If <span class="math inline">\(UPM_{UI} &gt; UPM_{EI}, UPM_{OI}\)</span>, then the current dose is likely an underdose, so our desire should be to escalate dose to <span class="math inline">\(i+1\)</span>.
In contrast, if <span class="math inline">\(UPM_{OI} &gt; UPM_{UI}, UPM_{EI}\)</span>, then the current dose is likely an overdose and we will want to de-escalate dose to <span class="math inline">\(i-1\)</span> for the next patient.
If <span class="math inline">\(UPM_{EI} &gt; UPM_{UI}, UPM_{OI}\)</span>, then the current dose is deemed sufficiently close to <span class="math inline">\(p_T\)</span> and we will want to stay at dose-level <span class="math inline">\(i\)</span>.</p>
<p>Further to these rules regarding dose-selection, the following rule is used to avoid recommending dangerous doses.
A dose is deemed inadmissible for being excessively toxic if</p>
<p><span class="math display">\[ Pr(p_{i} &gt; p_{T} | data) &gt; \xi,\]</span></p>
<p>for a certainty threshold, <span class="math inline">\(\xi\)</span>.
If a dose is excluded by this rule, it should not be recommended by the model.
Irrespective the values of <span class="math inline">\(UPM_{UI}, UPM_{EI}\)</span> and <span class="math inline">\(UPM_{OI}\)</span>, the design will recommend to stay at dose <span class="math inline">\(i\)</span> rather than escalate to a dose previously identified as being inadmissible.
Furthermore, the design will advocate stopping if the lowest dose is inferred to be inadmissible.</p>
<p>In their paper, the authors demonstrate acceptable operating performance using <span class="math inline">\(\alpha = \beta = 1\)</span>, <span class="math inline">\(\epsilon_{1} = 0.05\)</span>, <span class="math inline">\(\epsilon_{2} = 0.05\)</span> and <span class="math inline">\(\xi = 0.95\)</span>.
See <span class="citation">Ji et al. (2010)</span> for full details.</p>
<div id="implementation-in-escalation-1" class="section level3">
<h3>Implementation in <code>escalation</code></h3>
<p>Again, let us investigate one of the parameterisations that the authors investigate in their publication:</p>
<pre class="r"><code>library(escalation)

model &lt;- get_mtpi(num_doses = 5, target = 0.3, alpha = 1, beta = 1, 
                  epsilon1 = 0.05, epsilon2 = 0.05, exclusion_certainty = 0.95)</code></pre>
<p>As before, we fit the model and learn the dose recommended for the next patient(s) using:</p>
<pre class="r"><code>fit &lt;- model %&gt;% fit(&#39;1NNT&#39;) 
fit %&gt;% recommended_dose()</code></pre>
<pre><code>## [1] 1</code></pre>
<p>In their Figure 2, the authors again enumerate model advice over a range of cohort outputs.
Just as we did with TPI, enumerating the dose recommendations after a cohort of 6 has been treated at dose 2:</p>
<pre class="r"><code>model %&gt;% 
  get_dose_paths(cohort_sizes = 6, next_dose = 2) %&gt;% 
  graph_paths()</code></pre>
<div id="htmlwidget-2" style="width:672px;height:480px;" class="grViz html-widget"></div>
<script type="application/json" data-for="htmlwidget-2">{"x":{"diagram":"digraph {\n\ngraph [layout = \"neato\",\n       outputorder = \"edgesfirst\",\n       bgcolor = \"white\"]\n\nnode [fontname = \"Helvetica\",\n      fontsize = \"10\",\n      shape = \"circle\",\n      fixedsize = \"true\",\n      width = \"0.5\",\n      style = \"filled\",\n      fillcolor = \"aliceblue\",\n      color = \"gray70\",\n      fontcolor = \"gray50\"]\n\nedge [fontname = \"Helvetica\",\n     fontsize = \"8\",\n     len = \"1.5\",\n     color = \"gray80\",\n     arrowsize = \"0.5\"]\n\n  \"1\" [label = \"2\", fontcolor = \"#FDE725FF\", fillcolor = \"#2A788EFF\"] \n  \"2\" [label = \"3\", fontcolor = \"#440154FF\", fillcolor = \"#22A884FF\"] \n  \"3\" [label = \"3\", fontcolor = \"#440154FF\", fillcolor = \"#22A884FF\"] \n  \"4\" [label = \"2\", fontcolor = \"#FDE725FF\", fillcolor = \"#2A788EFF\"] \n  \"5\" [label = \"2\", fontcolor = \"#FDE725FF\", fillcolor = \"#2A788EFF\"] \n  \"6\" [label = \"1\", fontcolor = \"#7AD151FF\", fillcolor = \"#414487FF\"] \n  \"7\" [label = \"1\", fontcolor = \"#7AD151FF\", fillcolor = \"#414487FF\"] \n  \"8\" [label = \"1\", fontcolor = \"#7AD151FF\", fillcolor = \"#414487FF\"] \n\"1\"->\"2\" [label = \"NNNNNN\"] \n\"1\"->\"3\" [label = \"NNNNNT\"] \n\"1\"->\"4\" [label = \"NNNNTT\"] \n\"1\"->\"5\" [label = \"NNNTTT\"] \n\"1\"->\"6\" [label = \"NNTTTT\"] \n\"1\"->\"7\" [label = \"NTTTTT\"] \n\"1\"->\"8\" [label = \"TTTTTT\"] \n}","config":{"engine":"dot","options":null}},"evals":[],"jsHooks":[]}</script>
<p>We see that after <code>2NNNNNT</code>, the mTPI advocates escalation whereas TPI advocated sticking at dose 2.
The advice from the two models matches in all other outcomes.</p>
</div>
</div>
<div id="neuenschwander-et-al." class="section level2">
<h2>Neuenschwander <em>et al.</em></h2>
<p><span class="citation">Neuenschwander, Branson, and Gsponer (2008)</span> (NBG) introduced a derivative of the CRM for dose-escalation clinical trials using the model:</p>
<p><span class="math display">\[ \text{logit} p_i = \alpha + \exp{(\beta)} \log{(x_i / d^*)}, \]</span></p>
<p>where <span class="math inline">\(p_i\)</span> is the probability of toxicity at the <span class="math inline">\(i\)</span>th dose, <span class="math inline">\(x_i\)</span>, and <span class="math inline">\(d^*\)</span> is a reference dose.
Here <span class="math inline">\(\alpha\)</span> and <span class="math inline">\(\beta\)</span> are model parameters on which the authors place a bivariate normal prior.
This model is very similar to the two-parameter logistic CRM.
However, a notable difference is that the dose, <span class="math inline">\(x_i\)</span>, enters the model as a covariate.
This dispenses with the toxicity skeleton that is used in the CRM.</p>
<div id="implementation-in-escalation-2" class="section level3">
<h3>Implementation in <code>escalation</code></h3>
<p>The heavy lifting required to fit the model is performed by <code>trialr</code> and <code>rstan</code>.
<code>escalation</code> merely composes the model fit in such a way that it can be used with the other dose-selection modules.</p>
<p>For illustration, let us reproduce the analysis in <span class="citation">Neuenschwander, Branson, and Gsponer (2008)</span> that the authors used to demonstrate the flexibility of a two-parameter approach.
In a trial of 15 doses, the investigators saw outcomes:</p>
<pre class="r"><code>library(escalation)

dose &lt;- c(1, 2.5, 5, 10, 15, 20, 25, 30, 40, 50, 75, 100, 150, 200, 250)
outcomes &lt;- &#39;1NNN 2NNNN 3NNNN 4NNNN 7TT&#39;</code></pre>
<p>Creating a dose-escalation model with NBG’s parameters:</p>
<pre class="r"><code>model &lt;- get_trialr_nbg(real_doses = dose, d_star = 250, target = 0.3,
                        alpha_mean = 2.15, alpha_sd = 0.84,
                        beta_mean = 0.52, beta_sd = 0.8,
                        seed = 2020)</code></pre>
<p>and fitting the model to the observed outcomes:</p>
<pre class="r"><code>fit &lt;- model %&gt;% fit(outcomes)
fit</code></pre>
<pre><code>## Patient-level data:
## # A tibble: 17 x 4
##    Patient Cohort  Dose   Tox
##      &lt;int&gt;  &lt;int&gt; &lt;int&gt; &lt;int&gt;
##  1       1      1     1     0
##  2       2      1     1     0
##  3       3      1     1     0
##  4       4      2     2     0
##  5       5      2     2     0
##  6       6      2     2     0
##  7       7      2     2     0
##  8       8      3     3     0
##  9       9      3     3     0
## 10      10      3     3     0
## 11      11      3     3     0
## 12      12      4     4     0
## 13      13      4     4     0
## 14      14      4     4     0
## 15      15      4     4     0
## 16      16      5     7     1
## 17      17      5     7     1
## 
## Dose-level data:
## # A tibble: 15 x 7
##    RealDose  dose   tox     n empiric_tox_rate mean_prob_tox median_prob_tox
##       &lt;dbl&gt; &lt;int&gt; &lt;int&gt; &lt;int&gt;            &lt;dbl&gt;         &lt;dbl&gt;           &lt;dbl&gt;
##  1      1       1     0     3                0        0.0117         0.00511
##  2      2.5     2     0     4                0        0.0306         0.0186 
##  3      5       3     0     4                0        0.0644         0.0468 
##  4     10       4     0     4                0        0.134          0.114  
##  5     15       5     0     0              NaN        0.202          0.185  
##  6     20       6     0     0              NaN        0.264          0.251  
##  7     25       7     2     2                1        0.322          0.314  
##  8     30       8     0     0              NaN        0.374          0.370  
##  9     40       9     0     0              NaN        0.463          0.466  
## 10     50      10     0     0              NaN        0.535          0.543  
## 11     75      11     0     0              NaN        0.662          0.678  
## 12    100      12     0     0              NaN        0.741          0.760  
## 13    150      13     0     0              NaN        0.829          0.849  
## 14    200      14     0     0              NaN        0.875          0.894  
## 15    250      15     0     0              NaN        0.902          0.920  
## 
## The model targets a toxicity level of 0.3.
## The model advocates continuing at dose 7.</code></pre>
<p>we see that dose 7 is selected for the next cohort using the metric of selecting the dose with posterior expected probability of toxicity closest to the target.
In the above output, <code>mean_prob_tox</code> broadly matches the values plotted in the lower right panel of Figure 1 in <span class="citation">Neuenschwander, Branson, and Gsponer (2008)</span>.</p>
</div>
<div id="further-work" class="section level3">
<h3>Further work</h3>
<p>There are a few minor shortcomings of the NBG implementation in <code>escalation</code> &amp; <code>trialr</code>.
Firstly, NBG propose a bivariate normal prior distribution on <span class="math inline">\(\alpha\)</span> and <span class="math inline">\(\beta\)</span>.
However, the implementation in <code>trialr</code> currently uses independent normal priors.
Hopefully, this will be addressed in a future release of <code>trialr</code>.</p>
<p>Furthermore, NBG propose a method for selecting dose that accounts for the probability of recommending an overdose.
That logic is currently not implemented in <code>escalation</code>, but will be in the near future.</p>
</div>
</div>
<div id="mcmc-crm" class="section level2">
<h2>MCMC CRM</h2>
<p><code>escalation</code> already provides one-parameter CRM models via the <code>dfcrm</code> package <span class="citation">(Cheung 2013)</span>.
It now also provides MCMC implementations of those same one-parameter models:</p>
<pre class="r"><code>skeleton &lt;- c(0.05, 0.12, 0.25, 0.40, 0.55)
target &lt;- 0.25

model1 &lt;- get_trialr_crm(skeleton = skeleton, target = target, 
                         model = &#39;empiric&#39;, beta_sd = 1)
model2 &lt;- get_trialr_crm(skeleton = skeleton, target = target, 
                         model = &#39;logistic&#39;, a0 = 3, 
                         beta_mean = 0, beta_sd = 1)</code></pre>
<p>and also adds a two-parameter logistic model:</p>
<pre class="r"><code>model3 &lt;- get_trialr_crm(skeleton = skeleton, target = target, 
                         model = &#39;logistic2&#39;, 
                         alpha_mean = 0, alpha_sd = 2, 
                         beta_mean = 0, beta_sd = 1)</code></pre>
<p>For more on the parameterisation of these methods, check out the CRM vignette in the <a href="https://CRAN.R-project.org/package=escalation"><code>escalation</code></a>.</p>
</div>
<div id="simulations-and-dose-paths" class="section level2">
<h2>Simulations and dose-paths</h2>
<p>As with all methods in <code>escalation</code>, simulations are supported right out of the box.</p>
<p>For illustration, <span class="citation">Ji, Li, and Bekele (2007)</span> present a simulation study to compare the performance of their TPI design to some alternatives.
They specify a design that uses a maximum sample size of thirty patients:</p>
<pre class="r"><code>model &lt;- get_tpi(num_doses = 8, target = 0.25, k1 = 1, k2 = 1.5,
                 exclusion_certainty = 0.95) %&gt;%
  stop_at_n(n = 30)</code></pre>
<p>and their scenario 1 assumes true probability of toxicity:</p>
<pre class="r"><code>sc1 &lt;- c(0.05, 0.25, 0.5, 0.6, 0.7, 0.8, 0.9, 0.95)</code></pre>
<p>We can then reproduce their simulated characteristics by running:</p>
<pre class="r"><code>set.seed(123)
sims &lt;- model %&gt;%
  simulate_trials(num_sims = 50, true_prob_tox = sc1, next_dose = 1)

sims</code></pre>
<pre><code>## Number of iterations: 50 
## 
## Number of doses: 8 
## 
## True probability of toxicity:
##    1    2    3    4    5    6    7    8 
## 0.05 0.25 0.50 0.60 0.70 0.80 0.90 0.95 
## 
## Probability of recommendation:
## NoDose      1      2      3      4      5      6      7      8 
##   0.00   0.14   0.76   0.10   0.00   0.00   0.00   0.00   0.00 
## 
## Probability of administration:
##     1     2     3     4     5     6     7     8 
## 0.226 0.606 0.160 0.008 0.000 0.000 0.000 0.000 
## 
## Sample size:
##    Min. 1st Qu.  Median    Mean 3rd Qu.    Max. 
##      30      30      30      30      30      30 
## 
## Total toxicities:
##    Min. 1st Qu.  Median    Mean 3rd Qu.    Max. 
##    4.00    6.00    7.00    7.44    9.00   11.00 
## 
## Trial duration:
##    Min. 1st Qu.  Median    Mean 3rd Qu.    Max. 
##   15.30   27.50   30.75   30.65   34.90   42.30</code></pre>
<p>For the sake of speed, we ran just fifty iterations but in a real situation, many thousands of iterations would be more appropriate.</p>
</div>
<div id="conclusion" class="section level2">
<h2>Conclusion</h2>
<p>Amongst pure phase I designs, <code>escalation</code> now supports:</p>
<ul>
<li>CRM</li>
<li>TPI</li>
<li>mTPI</li>
<li>BOIN</li>
<li>NBG</li>
</ul>
<p>It also supports some designs that select dose by co-primary efficacy and toxicity outcomes, the so-called seamless phase I/II designs.
Those will be the subect of the next post on this blog.
Til then, good day.</p>
</div>
<div id="references" class="section level2 unnumbered">
<h2>References</h2>
<div id="refs" class="references">
<div id="ref-escalation">
<p>Brock, Kristian. 2020. <em>Escalation: Modular Approach to Dose Finding Clinical Trials</em>. <a href="https://CRAN.R-project.org/package=escalation">https://CRAN.R-project.org/package=escalation</a>.</p>
</div>
<div id="ref-dfcrm">
<p>Cheung, Ken. 2013. <em>Dfcrm: Dose-Finding by the Continual Reassessment Method</em>. <a href="https://CRAN.R-project.org/package=dfcrm">https://CRAN.R-project.org/package=dfcrm</a>.</p>
</div>
<div id="ref-Ji2007">
<p>Ji, Yuan, Yisheng Li, and B. Nebiyou Bekele. 2007. “Dose-finding in phase I clinical trials based on toxicity probability intervals.” <em>Clinical Trials</em> 4 (3): 235–44. <a href="https://doi.org/10.1177/1740774507079442">https://doi.org/10.1177/1740774507079442</a>.</p>
</div>
<div id="ref-Ji2010">
<p>Ji, Yuan, Ping Liu, Yisheng Li, and B. Nebiyou Bekele. 2010. “A modified toxicity probability interval method for dose-finding trials.” <em>Clinical Trials</em> 7 (6): 653–63. <a href="https://doi.org/10.1177/1740774510382799">https://doi.org/10.1177/1740774510382799</a>.</p>
</div>
<div id="ref-Neuenschwander2008">
<p>Neuenschwander, Beat, Michael Branson, and Thomas Gsponer. 2008. “Critical aspects of the Bayesian approach to phase I cancer trials.” <em>Statistics in Medicine</em> 27: 2420–39. <a href="https://doi.org/10.1002/sim.3230">https://doi.org/10.1002/sim.3230</a>.</p>
</div>
</div>
</div>
